On March 15, SIPO (State Intellectual Property Office) Commissioner Tian Lipu met with the visiting General counsel pharmaceutical of AstraZeneca G?ran Lerenius,and his party.  The two sides exchanged views on issues such as IPR protection, the third revision of China's Patent Law, and application for pharmaceutical patents.  Both expressed will to further such exchange and cooperation.
 
Commissioner Tian briefed the guests on China's latest IPR progress.  "Premier Wen Jiabao stressed, in his Government Work Report released at the recently-concluded 5th session of the 10th NPC, that the government shall stressed the formulation and implementation of national IP strategy and effectively protect intellectual property rights, which fully demonstrates the Chinese government's resolution in IPR protection." Tian said.  He noted that the Chinese government recognizes that it is an undertaking for China's own sake rather than a reaction to outside pressure to enhance IPR protection.  At present, inter-sectoral forces are joined within the government to work towards strengthened IPR protection.  Tian also hoped for bilateral cooperation in personnel training, the third revision of China's Patent Law, pharmaceutical patent application, and etc.
 
G?ran Lerenius congratulated on China's IPR achievements.  He pointed out that China is a major market for AstraZeneca's global operations, with USD100 million invested in Shanghai to build a R&D center.  He added that more would follow to expand its R&D work in China as an effort to aspire for intensified exchanges and cooperation between the two sides.

2007-04-05

2007-04-05